Compare Freeport-McMoRan Inc (FCX) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Freeport-McMoRan Inc trades at $68.2 (market cap $99.98B), while GE HealthCare Technologies Inc. Common Stock trades at $69.4 (market cap $30.93B). The key difference: Freeport-McMoRan Inc is far larger — about 3.2× GE HealthCare Technologies Inc. Common Stock's market cap, and Freeport-McMoRan Inc pays the higher dividend (0.86%). Which is the better fit depends on your goals.
| FCX | GEHC | |
|---|---|---|
Market Cap | $99.98B | $30.93B |
Volume | 12,433,733 | 5,033,451 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $88.16 |
52-Week Low | $38.65 | $59.48 |
Typical Hold Time | 70 Days | — |
Enterprise Value | $106.25B | $39.39B |
Dividend Yield | 0.86% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $72.42, down 1.19% on the day, with a bullish technical outlook supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue grew to $25.92B in 2025, and net income improved to $2.20B. Analysts maintain a strong buy consensus with a $73.50 price target, citing copper demand growth from AI and data centers.
The stock offers exposure to rising copper demand driven by AI infrastructure, with expansion projects poised to boost output. Risks include rising production costs, regulatory investigations, and commodity price volatility. Institutional sentiment is positive, but investors should monitor cost pressures and execution of growth initiatives.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
